Kexing Biopharm’s Overseas Product Paclitaxel for lnjection (Albumin Bound) Approved for Marketing in the UAE

Article source：May 21,2026View： 365

Recently, Kexing Biopharm’s overseas anti-tumor product—Paclitaxel for lnjection (Albumin Bound) (Apexelsin®)—has officially obtained marketing authorization from the Emirates Drug Establishment (EDE), entering the core pharmaceutical market of the Middle East.

UAE: A High-Growth Pharmaceutical Market in the Middle East

The United Arab Emirates is one of the most economically dynamic countries in the Middle East. According to Statista, the UAE’s GDP reached USD 456.56 billion in 2023, with a per capita GDP of nearly USD 47,000, classifying it as a high-income country. In addition, IQVIA reports indicate that the UAE pharmaceutical market has continued to grow in both size and growth rate in recent years, ranking second in the Middle East and Africa region.

Research shows that breast cancer accounts for 25% of all cancer cases in the UAE and 43% of female cancer cases, making it the second leading cause of cancer-related deaths among women. Albumin-bound paclitaxel is recommended in the European Society for Medical Oncology (ESMO) guidelines as a first-line treatment option for multiple solid tumors, including breast cancer, non-small cell lung cancer, and metastatic pancreatic cancer. The approval of Apexelsin® will provide additional treatment options for cancer patients in the UAE.

Clinical Advantages of Albumin-bound Paclitaxel

Paclitaxel for Injection (Albumin-bound) offers notable clinical advantages. Compared with conventional paclitaxel injection and paclitaxel liposome formulations, it demonstrates improved safety and better patient compliance. It is widely recognized in clinical practice and holds indispensable value in oncology treatment.

Expanding Global Presence of Apexelsin®

As a flagship overseas product of Kexing Biopharm, Apexelsin® obtained marketing approval from the European Commission in 2024. It has since been approved in more than 30 countries and regions, including the United Kingdom, Peru, Uruguay, Argentina, Oman, Malaysia, Macao (China), Georgia, the Dominican Republic, and the Philippines.

The product has established a global commercialization network spanning Europe, Latin America, Southeast Asia, and the Middle East. The high-standard regulatory approval in the European Union has also strongly facilitated its market entry into emerging markets.

Looking ahead, the company will continue to deepen its presence in overseas markets, advancing the global accessibility of high-quality pharmaceutical products and benefiting more patients worldwide.